Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022. “We continue to execute well on our three strategic pillars to build out Aerie version 2.0. I am pleased to report stron